Lipoteichoic Acid anticorps

N° du produit ABIN7232846

L’anticorps Souris Monoclonal anti-Lipoteichoic Acid a été validé pour ELISA. Il convient pour détecter Lipoteichoic Acid dans des échantillons de Gram Positive Bacteria.

Aperçu rapide pour Lipoteichoic Acid anticorps (ABIN7232846)

Antigène: Lipoteichoic Acid (LTA)

Reactivité: Gram Positive Bacteria

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Lipoteichoic Acid est non-conjugé

Application: ELISA

Clone: 15711

Détail du produit anti-Lipoteichoic Acid anticorps

Fonction: Anti-Lipoteichoic Acid Mouse Monoclonal Antibody

Specificité: This antibody reacts with lipoteichoic acid of Staph epidermidis, Hay strain, as well as clinical strains of Staph. epidermidis (types I, II, and III), Staph. aureus strains 5 and 8, Strep. pyogenes, Strep. fecaelis, and Strep. mutans. It does not react with peptido- glycan of Staph. aureus or peptidoglycan- rhamnose, nor does it react with pneumococcal polysaccharides. This antibody does not cross-react with E. coli or H. influenzae type B.

Réactivité croisée: Gram Positive Bacteria

Immunogène: Staphylococcus epidermidis, Hay strain (ATCC #55133).

Isotype: IgG1

Information d'application

Indications d'application: ELISA: use at 0.1-1.0 μg/mL (optimized for LTA on solid phase).
Opsonization assay: use at 80-160 μg/mL (optimized for Staph. epidermidis, Hay strain).

Restrictions: For Research Use only

Stockage

Format: Liquid

Reconstitution: Dilute in PBS or medium that is identical to that used in the assay system.

Concentration: Lot specific

Buffer: PBS, pH 7.4

Stock: -20 °C

Stockage commentaire: This antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze-thaw cycles.

Détails sur Lipoteichoic Acid

Antigène: Lipoteichoic Acid (LTA)

Autre désignation: Lipoteichoic acid

Classe de substances: Chemical

Sujet: Lipoteichoic acid (LTA) is the major proinflammatory structure present within the cell wall layer of most gram-positive bacteria. It plays an important role in the initiation and progression of bacterial infection, inflammation, and septic shock. LTA induces several cytokines in vivo, and LTA and peptidoglycan (PepG) synergize to cause the induction of nitric oxide formation which can lead to multiple organ failure. Since LTA is also found in the cell walls of non-pathogenic gram-positive bacteria, it has been suggested that the structure of LTA , and its ability to synergize with PepG, determines the ability of a particular bacterium to cause septic shock.